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Deoxyglycychloxazol (TY501) is a glycyrrhetinic acid derivative which exhibits high anti-inﬂammatory
activity and reduced pseudoaldosteronism compared to glycyrrhetinic acid. In this study, a sensitive and
rapid liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was established for the
quantitation of TY501 in rat plasma. Plasma samples were treated by precipitating protein with methanol
and supernatants were separated by a Symmetry C8 column with the mobile phase consisting of me-
thanol and 10 mM ammonium formate (containing 0.1% of formic acid) (90:10, v/v). The selected reaction
monitoring (SRM) transitions were performed at m/z 647.4-191.2 for TY501 and m/z 473.3-143.3 for
astragaloside aglycone (IS) in the positive ion mode with atmospheric pressure chemical ionization
(APCI) source. Calibration curve was linear over the concentration range of 5–5000 ng/mL. The lower
limit of quantiﬁcation was 5 ng/mL. The mean recovery was over 88%. The intra- and inter-day precisions
were lower than 6.0% and 12.8%, respectively, and the accuracy was within 71.3%. TY501 was stable
under usual storage conditions and handling procedure. The validated method has been successfully
applied to a pharmacokinetic study after oral administration of TY501 to rats at a dosage of 10 mg/kg.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liquorice, the root of glycyrrhiza spp., has been used clinically
over centuries in China and proved to have antibacterial, cardiac,
anti-inﬂammatory and tonic activities [1–3]. Glycyrrhetinic acid is
the sapogenin of glycyrrhizic acid, a major bioactive component of
liquorice, which can relieve peptic ulcer, enhance immunity, and
present anti-inﬂammatory, hepatoprotective and other activities
[1,3,4]. However, it has been found that pseudoaldosteronism is
usually induced by glycyrrhetinic acid. In this case, the effect of
sodium retention and potassium excretion can be enhanced dra-
matically, leading to edema, hypertension and hypopotassemia.
[1,5–7].
Deoxyglycychloxazol (TY501, Fig. 1A) is a glycyrrhetinic acid
derivative which is designed and synthesized to reduce the
pseudoaldosteronism by destructing the 11-oxo system in ring C
[8,9]. On the other hand, therapeutic activities are retained and
enhanced by modiﬁcation of the terminal carboxyl attached toon and hosting by Elsevier B.V. Th
University.ring E with isoxazole of glycyrrhetinic acid [10–12]. According to
the pharmacodynamic studies [11–15], promising anti-in-
ﬂammatory, anti-ﬁbrotic, anti-gastric ulcer and other activities as
well as limited hepatorenal damage and gastrointestinal reaction
were observed. It is suggested that TY501 is much safer than other
existing steroid and non-steroid anti-inﬂammatory drug entities;
it, therefore, has the potential to be a good drug candidate. To
evaluate and understand the pharmacokinetic properties of TY501,
we developed a simple and rapid bioanalytical method for quan-
tiﬁcation of TY501 in biological samples for preclinical and clinical
pharmacokinetics studies.
Compared with other detection techniques, mass spectrometry
is considered as the most speciﬁc and sensitive approach for most
chemicals, and becomes the ﬁrst choice of quantitation for low
molecular weight drugs in biological samples. To the best of our
knowledge, the pharmacokinetics of TY501 has not been studied
by liquid chromatography–tandem mass spectrometry (LC–MS/
MS). In this study, a rapid, simple and sensitive LC–MS/MS method
for the quantitation of TY501 in rat plasma has been developed
and validated. The method has several advantages, including small
volume plasma sample (50 μL), simple sample preparation (pro-
tein precipitation), good chromatographic resolution, speciﬁc andis is an open access article under the CC BY-NC-ND license
Fig. 1. Structures of (A) deoxyglycychloxazol and (B) astragaloside aglycone.
Fig. 2. Product ion mass spectra of (A) deoxyglycychloxazol and (B) astragaloside
aglycone.
R. Li et al. / Journal of Pharmaceutical Analysis 6 (2016) 184–189 185sensitive mass spectrometric conditions and the broad con-
centration range of 5–5000 ng/mL. The method established was
then successfully applied to determine the plasma concentration
of TY501 for a pharmacokinetic study after oral administration to
rats at a dosage of 10 mg/kg.2. Experimental
2.1. Chemicals and reagents
TY501 (Purity 99.6%) and astragaloside aglycone (Purity 99.5%)(IS, Fig. 1B) were both kindly provided by the Laboratory of Med-
icinal Chemistry, Tianjin Institute of Pharmaceutical Research
(Tianjin, China). Methanol of HPLC grade was purchased from
Tianjin Concord Tech. Reagent Co., Ltd. (Tianjin, China). Ammo-
nium formate and other reagents were of analytical grade. Deio-
nized water was used throughout the experiment.
2.2. Chromatography conditions
Chromatographic separation was carried out on a Symmetry C8
column (50 mm4.6 mm, 5 mm; Waters Corp., Milford, MA, USA)
using a Shimadzu UFLC system equipped with a binary pump, a
vacuum degasser and an autosampler (Shimadzu Corporation,
Kyoto, Japan). The column oven was maintained at 40 °C. The
mobile phase consisting of methanol and 10 mM ammonium for-
mate (containing 0.1% of formic acid) (90:10, v/v) was performed
at a ﬂow rate of 0.5 mL/min. The samples were kept at 4 °C in the
autosampler.
2.3. Mass spectrometry conditions
The mass spectrometry was performed on an API 4000 QTraps
mass spectrometer (Applied Biosystems Sciex, Toronto, Canada).
Analyst 1.5 software was used for data acquisition and analysis
(Applied Biosystems Sciex, Toronto, Canada). Ionization was op-
erated using an atmospheric pressure chemical ionization (APCI)
source in positive ion mode. The APCI source was operated with an
ionspray voltage of 5000 V. The nebulizer gas was nitrogen de-
livered at 30 psi. The capillary temperature was 320 °C. The curtain
gas and collision gas were 10 psi and 6 psi, respectively. The value
of corona discharge needle was 5 μA. The collision cell exit po-
tential was 10 V. The MS recordings were carried out in selected
reaction monitoring (SRM) mode with speciﬁc ion transitions of
precursor ion to product ion at m/z 647.4-191.2 with collision
energy (CE) of 38 eV, declustering potential (DP) of 85 V and en-
trance potential (EP) of 15 V for TY501, and at m/z 473.3-143.3
with CE of 23 eV, DP of 55 V and EP of 10 V for IS. The total ana-
lytical time was 5 min.
2.4. Calibration standard and quality control samples preparation
The stock solution of TY501 (1.0 mg/mL) was prepared in me-
thanol, and further diluted with methanol to obtain the working
solutions at the concentrations of 5, 10, 50, 200, 1000, 2000 and
5000 ng/mL. The IS stock solution (1.0 mg/mL) was diluted with
methanol to get the concentration of 0.96 μg/mL. All the solutions
were kept at 4 °C and brought to room temperature before use.
The 50 μL of working solution of TY501 was evaporated to
dryness at 40 °C under a gentle stream of nitrogen, and then 50 μL
of blank rat plasma was added, which was vigorously vortex-
mixed for 30 s. The concentration levels of TY501 in plasma ranged
from 5 to 5000 ng/mL. Quality control (QC) samples were prepared
in a similar manner at low, medium and high levels (10, 200,
Fig. 3. SRM chromatograms of (A) blank rat plasma; (B) blank rat plasma spiked with deoxyglycychloxazol (LLOQ, 5 ng/mL) and IS (0.96 mg/mL); (C) blank rat plasma spiked
with deoxyglycychloxazol (1000 ng/mL) and IS (0.96 mg/mL); (D) a rat plasma sample at 5 h after oral administration of 10 mg/kg of deoxyglycychloxazol.
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Table 1
Precision and accuracy of deoxyglycychloxazol in rat plasma.
Concentration (ng/mL) Precision (RSD (%)) Accuracy (RE (%))
Spiked Measured (Mean7SD) Intra-day Inter-day
5 (LLOQ) 4.770.3 5.2 11.6 4.8
10 10.070.6 6.0 3.1 0.0
200 20078.7 3.8 7.3 0.1
4000 40507225 3.6 12.8 1.3
Table 2
Stability of deoxyglycychloxazol in rat plasma (n¼3).
Storage conditions Concentration (ng/mL) RE (%)
Spiked Measured (Mean7SD)
At room temperature for 24 h 10 9.970.2 0.6
200 194.074.0 3.0
4000 4070.07125.8 1.8
Three freeze-thaw cycles 10 10.370.9 3.0
200 191.077.8 4.5
4000 3890.07141.8 2.8
At 4 °C in the autosampler for 24 h 10 9.870.6 2.1
200 195.077.0 2.5
4000 40307143.0 0.8
At 20 °C for 30 days 10 9.570.9 4.9
200 189.077.0 5.5
4000 3935.7787.9 1.6
Fig. 4. Mean plasma concentration–time proﬁle of deoxyglycychloxazol after a
single oral administration of 10 mg/kg to rats (n¼6, Mean7SD).
Table 3
Main pharmacokinetic parameters of deoxyglycychloxazol after oral administration
of 10 mg/kg to rats (Female/male: n¼3, Total: n¼6, Mean7SD).
Pharmacokinetic parameters Deoxyglycychloxazol
Female Male Total
Cmax (ng/mL) 563793.3 388736.2 4757115
Tmax (h) 870 870 870
t1/2 (h) 35.2720.1 82.0717.0 58.6730.6
CL (L/kg h) 585778.1 5657199 5757136
AUC0t (ng h/mL) 11,98572573 11,66872636 11,82772336
AUC01 (ng h/mL) 15,13574976 19,34476140 17,23975505
Cmax: the maximum plasma concentration.
Tmax: the time to reach peak concentration.
t1/2: the terminal elimination half-life.
CL: the plasma clearance.
AUC0t: the area under the curve from zero to the last sampling time.
AUC01: the AUC0t extrapolated to inﬁnity.
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prepared from the same stock solution. All the spiked plasma
samples were then treated according to sample preparation pro-
cedure. Both the calibration standard samples and the QC samples
were used in the method validation and the pharmacokinetic
study.
2.5. Sample preparation
A total of 50 μL of plasma sample was added with 250 μL of IS
working solution (0.96 μg/mL) in polypropylene tube. Subse-
quently, the tube was vigorously vortex-mixed for 30 s to pre-
cipitate plasma proteins and centrifuged (12,000 rpm, Refrigerated
centrifuge SIGMA 3K15, Osterode am Harz, Germany) for 10 min.
The supernatant was transferred to an injection vial and then an
aliquot of 20 μL of the supernatant was injected for LC–MS/MS
analysis.
2.6. Method validation
2.6.1. Selectivity
Six different rat blank plasma samples were prepared and
analyzed to investigate potential interferences of endogenous
compounds. The chromatogram of blank plasma sample was
compared with those of plasma samples spiked with the analyte
and IS and incurred plasma sample after oral administration of
TY501.
2.6.2. Linearity
To evaluate linearity of this method, calibration standards were
prepared and analyzed in triplicate on three consecutive days.
Calibration curves were constructed by plotting the peak area ratio
(analyte/IS) versus the spiked concentrations of TY501 by least
square linear regression analysis with a weighting factor of 1/x2.
Deviations of these back-calculated concentrations from calibra-
tion standard samples were set within 715% of nominal con-
centrations (720% for the lower limit of quantitation (LLOQ)).
2.6.3. Precision and accuracy
Precision and accuracy were assessed by determining six re-
plicates of the low, medium and high QC samples (10, 200,
4000 ng/mL) on three consecutive days. The precision was ex-
pressed as the relative standard deviation (RSD) and the accuracy
was described as the relative error (RE). The acceptable intra- and
inter-day precision is required to be less than 15% and the accep-
table accuracy is required to be within 715% for all QC samples.
2.6.4. LLOQ
The LLOQ of the assay was assessed as the lowest concentration
of the calibration curve that can be quantitatively determined with
acceptable precision less than 20% and accuracy within 720%. The
LLOQ was established based on six replicates on three consecutive
days.
2.6.5. Matrix effect
The matrix effect was deﬁned as the ion suppression/en-
hancement on the ionization of the analytes, which was evaluated
by comparing the corresponding peak areas of the post-extraction
spiked samples to those of the standard solutions evaporated di-
rectly and reconstituted in mobile phase. Experiments were per-
formed at the three QC levels, in six replicates.
2.6.6. Recovery
The extraction recoveries of TY501 and IS were estimated by
comparing the peak areas obtained from these prepared plasma
samples described above with those obtained from direct injection
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centrations. Experiments were performed at three QC concentra-
tion levels, in six replicates.
2.6.7. Stability
The stability of TY501 in rat plasma was investigated by com-
paring the measured concentrations of low, medium and high QC
samples (in triplicate) with the spiked concentrations under the
following four storage conditions: (i) stability of the analyte in
plasma was assessed by placing QC samples for 24 h at room
temperature and then extracted for analysis; (ii) for freeze–thaw
stability, QC samples were determined through three freeze
(20 °C)–thaw (room temperature) cycles; (iii) to evaluate the
stability of the treated plasma samples in the autosampler, QC
samples were prepared and placed in the autosampler at 4 °C for a
period of 24 h, and then injected for analysis; (iv) for long-term
storage stability, QC samples were prepared and stored at 20 °C
for 30 days. The analyte was considered stable when the percent
deviation was within 715%.
2.7. Pharmacokinetic study
Six Wistar rats (male and female, weighting 200720 g, Certi-
ﬁcate No.: SCXK (jing) 2006–0009) were purchased from Beijing
Marshall Biotechnology Co., Ltd. (Beijing, China). The rats were
housed under controlled environmental conditions (temperature
20–22 °C; humidity 45%–65%) and had ad libitum access to water
and to a standard laboratory diet. The experimental protocols
concerning the animal care and use for this study were approved
by Institutional Animal Care and Use Committee of Tianjin In-
stitutes (China). Before oral administration, the rats were fasted for
12 h but with access to water, and further fasted for 2 h after
administered. TY501 was suspended in 0.5% carboxymethyl
cullulose sodium (CMC-Na) solution and orally administrated to
each rat at a dosage of 10 mg/kg. 0.1 mL of blood samples were
collected in heparinized tubes pre-dose and at 0.5, 1, 2, 3, 5, 8, 12,
24, 32, 48, 56, 72 and 96 h post-dose. Plasma samples were ob-
tained by centrifugation at 3000 rpm for 10 min. All plasma sam-
ples were stored at 20 °C and analyzed within a month.
Non-compartment model was used to calculate the pharma-
cokinetic parameters with DAS 2.0 software. The area under the
curve from zero to the last sampling time (AUC0t) was calculated
by trapezoidal method. The terminal elimination half-life (t1/2)
was then calculated as 0.693/ke. Plasma clearance (Cl) was calcu-
lated as Dose/AUC.3. Results and discussion
3.1. Chromatographic conditions
Multiple chromatographic conditions were explored in order to
have appropriate retention time, and better resolution and sensi-
tivity. Symmetry C18 column (50 mm4.6 mm) and C8 column
(50 mm4.6 mm) were evaluated to attain better separation. It
was found that the binding of TY501 on C18 column was quite
strong; therefore it could not be eluted easily. In comparison, C8
column showed shorter retention time and better peak shape than
C18 column and was ﬁnally chosen for the chromatographic se-
paration. The mobile phase consisting of methanol and 10 mM
ammonium formate (containing 0.1% of formic acid) (90:10, v/v)
was found to be optimal for this study. Better chromatographic
separation and higher response were obtained using methanol
than acetonitrile. The addition of 10 mM ammonium formate and
formic acid was believed to be able to have better peak shape;
thus, the sensitivity can be enhanced. In addition, under theoptimized conditions, no signiﬁcant endogenous interference was
found.
3.2. Mass spectrometric conditions
Electron spray ionization (ESI) and APCI are the most com-
monly used soft ionization sources in mass spectrometry. Al-
though the product ion mass spectra of TY501 using ESI- and
APCI-MS were similar in terms of full-scan and fragmentation, a
higher response and less susceptibility to the matrix can be
achieved by APCI. Accordingly, APCI, rather than ESI, as the ioni-
zation source, was chosen in this study. By investigating the full-
scan mass spectra of TY501, it was found that the signal intensity
in the positive mode was much higher than that in the negative
ion mode. Thus, all detections were carried out using the pre-
dominantly positive ion mode. The full-scan positive ion mass
spectrum showed that TY501 and IS were protonated molecular
ion ([MþH]þ) of m/z 647.4 and dehydrated protonated molecular
ion ([MþH-H2O]þ) of m/z 473.3, respectively. After fragmentation
in the collision cell, the most abundant and stable product ions
(Fig. 2) were at m/z 191.2 for TY501 and at m/z 143.3 for IS, re-
spectively. The collision-induced dissociation (CID) parameters
were optimized to enhance the response and speciﬁcity using the
SRM mode comprising the precursor and product ions. The most
suitable mass spectrometric conditions were determined by opti-
mizing all the parameters of the mass spectrometer such as col-
lision energy, nebulizer gas, curtain gas, collision gas, spray voltage
and capillary temperature to obtain much higher and more stable
response.
3.3. Sample preparation
A number of samples need to be analyzed in pharmacokinetic
study. Thus, a simple, rapid and convenient sample preparation is
necessary and critical. Several liquid chromatography-mass spec-
trometry (LC–MS) or LC–MS/MS studies on the quantitation of
glycyrrhetinic acid in human plasma samples have been reported
in literature [16–19]. Most of the methods used liquid-liquid ex-
traction (LLE) and solid phase extraction (SPE) steps for sample
processing. Protein precipitation was chosen for the sample pre-
paration in this study, since it was much easier to handle and less
time-consuming; most importantly, the extraction recoveries of
TY501 were very close in the three sample pretreatment
processes.
3.4. Method validation
3.4.1. Selectivity and speciﬁcity
The selectivity of the method was investigated by comparing
chromatograms of blank plasma, spiked plasma and rat plasma
after oral administration of TY501. The retention time was 3.0 and
1.7 min for TY501 and IS, respectively (Fig. 3). As shown in the
ﬁgures, there were no signiﬁcant endogenous peaks that could
interfere with the analyte and IS. The results indicated that the
method exhibited good speciﬁcity and selectivity and was ap-
plicable to plasma samples for the pharmacokinetic study.
3.4.2. LLOQ
Calibration curves were linear over the concentration range of
5–5000 ng/mL. The typical regression equation obtained by least
square regression was y¼0.0315xþ0.0007, where y is the peak
area ratio of the analyte to IS, and x is the concentration of the
analyte. The correlation coefﬁcient (r2) was Z0.99 for all calibra-
tion curves, and the observed deviation was within 715% for all
calibration concentrations. The LLOQ of TY501 was measured to be
5 ng/mL. The intra- and inter-day precisions of the LLOQ were
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(Table 1), which was sufﬁcient for pharmacokinetic studies of
TY501 in rats.
3.4.3. Precision and accuracy
QC samples at three concentrations were analyzed in six re-
plicates in order to determine the assay accuracy and precision. As
shown in Table 1, the intra- and inter-day precisions were within
76.0% and 712.8%, and the accuracy was within 71.3% for
TY501, which indicated that the present method has a satisfactory
accuracy and precision.
3.4.4. Matrix effect
The ion suppression/enhancement of TY501 in signal ranged
from 6.5% to 12.4% for three QC levels, indicating that the matrix
effect on the ionization of the analyte is not obvious under these
conditions.
3.4.5. Recovery
Under the given set of operating condition, the extraction re-
coveries of TY501 in rat plasma were (88.974.6)%, (89.672.5)%
and (91.072.3)% at concentrations of 10, 200 and 4000 ng/mL.
The mean absolute recovery of the IS was 96.1%.
3.4.6. Stability
Results of the stability tests for TY501 are shown in Table 2. It
can be seen that TY501 was stable in rat plasma samples under
various storage and analysis conditions, including being placed at
room temperature for 24 h and being stored at –20 °C for 30 days
or through three freeze-thaw cycles. On the other hand, processed
samples were found to be stable at 4 °C in the autosampler for a
period of 24 h, indicating that a large number of samples could be
processed in each analytical run.
3.5. Pharmacokinetic study
The mean plasma concentration-time proﬁle following oral
administration of TY501 to rats is shown in Fig. 4. The main
pharmacokinetic parameters of TY501 are calculated and de-
monstrated in Table 3. The Cmax and t1/2 were different between
male and female rats, which suggests that the absorption and
metabolism of deoxyglycychloxazol may be affected by genders.4. Conclusion
A simple, sensitive, selective and novel LC–MS/MS method was
established for the determination of TY501 in rat plasma. Thepresent method employed a simple and rapid protein precipitation
procedure for sample preparation, and a high sensitivity could be
achieved, with the LLOQ of 5 ng/mL for TY501. Furthermore, only a
limited amount of plasma sample (50 μL) was needed for the
analysis. The method has been successfully validated via an oral
pharmacokinetic study of TY501 in rats.References
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